CEP85L

Across TCGA pan-cancer cohorts, CEP85L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP85L data layer compared with 26 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher CEP85L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP85L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, BRCA, and UCEC are the cancer types where CEP85L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	30	view →
BRCA	DFS	Median	II,III,IV	0.269	0.890	<.001	24	view →
UCEC	DFS	Median	All	0.970	0.614	.004	20	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP85L–SCLC (OS)

Open the SCLC breakdown →